PT2274331E - Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações - Google Patents

Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações Download PDF

Info

Publication number
PT2274331E
PT2274331E PT97382527T PT09738252T PT2274331E PT 2274331 E PT2274331 E PT 2274331E PT 97382527 T PT97382527 T PT 97382527T PT 09738252 T PT09738252 T PT 09738252T PT 2274331 E PT2274331 E PT 2274331E
Authority
PT
Portugal
Prior art keywords
binding molecules
based binding
improved fibronectin
fibronectin
improved
Prior art date
Application number
PT97382527T
Other languages
English (en)
Inventor
John Hastewell
Andreas Loew
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41114864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2274331(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2274331E publication Critical patent/PT2274331E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
PT97382527T 2008-05-02 2009-05-04 Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações PT2274331E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5014208P 2008-05-02 2008-05-02

Publications (1)

Publication Number Publication Date
PT2274331E true PT2274331E (pt) 2014-02-27

Family

ID=41114864

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97382527T PT2274331E (pt) 2008-05-02 2009-05-04 Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
PT111913794T PT2439212T (pt) 2008-05-02 2009-05-04 Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111913794T PT2439212T (pt) 2008-05-02 2009-05-04 Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações

Country Status (14)

Country Link
US (3) US9296810B2 (pt)
EP (4) EP2439212B1 (pt)
JP (3) JP6192891B2 (pt)
KR (1) KR20110021832A (pt)
CN (1) CN102076713B (pt)
AU (1) AU2009242038B2 (pt)
BR (1) BRPI0913007A2 (pt)
CA (1) CA2723277A1 (pt)
EA (1) EA201001734A1 (pt)
ES (2) ES2620285T3 (pt)
MX (1) MX2010011957A (pt)
PL (2) PL2439212T3 (pt)
PT (2) PT2274331E (pt)
WO (1) WO2009133208A1 (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ATE516814T1 (de) * 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
PT2274331E (pt) 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20120270797A1 (en) * 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
WO2011051333A1 (en) * 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011092233A1 (en) * 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011103105A1 (en) * 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
AU2011240620A1 (en) 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
MX392483B (es) * 2010-04-13 2025-03-24 Bristol Myers Squibb Co Proteínas de dominio de armazón basadas en fibronectina que se unen a la proteína convertasa subtilisina kexina tipo q (pcsk9).
PT3103478T (pt) 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
AU2016203044B2 (en) * 2010-05-03 2017-12-14 Bristol-Myers Squibb Company Serum albumin binding molecules
AU2013202913B2 (en) * 2010-05-03 2016-06-16 Bristol-Myers Squibb Company Serum albumin binding molecules
EP3091028A1 (en) * 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
SG187225A1 (en) 2010-07-30 2013-02-28 Novartis Ag Fibronectin cradle molecules and libraries thereof
KR101830344B1 (ko) * 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
DK2697257T3 (en) 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
EP2710382B1 (en) 2011-05-17 2017-10-18 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
CN110725009B (zh) 2011-09-27 2024-01-30 詹森生物科技公司 具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX366666B (es) 2012-09-13 2019-07-19 Bristol Myers Squibb Co Proteínas del dominio de soporte basadas en fibronectina que se fijan a miostatina.
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2870802T3 (es) 2013-02-12 2021-10-27 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
KR102478402B1 (ko) * 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
ES2898273T3 (es) 2014-03-20 2022-03-04 Bristol Myers Squibb Co Moléculas con una estructura a base de fibronectina estabilizada
ES2736127T3 (es) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
ES2941895T3 (es) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III)
CA2969067A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CA2983276A1 (en) 2015-04-24 2016-10-27 Viiv Healthcare Uk (No 5) Limited Polypeptides targeting hiv fusion
BR112017023829A2 (pt) 2015-05-06 2018-07-31 Janssen Biotech Inc agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
CN108290941A (zh) 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
CN108884147B (zh) 2015-09-23 2024-02-27 百时美施贵宝公司 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
KR102461666B1 (ko) * 2016-06-03 2022-11-01 얀센 바이오테크 인코포레이티드 혈청 알부민 결합 피브로넥틴 iii 형 도메인
SG11201811062XA (en) 2016-06-21 2019-01-30 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
TWI897843B (zh) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
JP2021507717A (ja) 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
BR112020016454A8 (pt) 2018-02-12 2022-08-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Tratamento utilizando rna que codifica citocina
JP7550745B2 (ja) 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
EP3920960B1 (en) 2019-02-08 2024-04-17 Biontech Cell & Gene Therapies Gmbh Treatment involving car-engineered t cells and cytokines
JP7775078B2 (ja) 2019-03-18 2025-11-25 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
EP4110407A1 (en) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
JP2023518935A (ja) 2020-03-16 2023-05-09 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
CN111748035B (zh) * 2020-05-20 2022-03-04 科稷达隆(北京)生物技术有限公司 一组新型的fn3类抗体突变体及其应用
EP4243854A4 (en) * 2020-11-10 2024-12-11 New York University Npc1 monobodies and monobody conjugates thereof
EP4243874A4 (en) * 2020-11-10 2024-10-16 New York University Macropinocytosis selective monobody-drug conjugates
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
JP2024514364A (ja) 2021-04-12 2024-04-01 ビオンテック・ソシエタス・エウロパエア 緩衝物質を含むｒｎａ組成物ならびにその製造、保存および使用のための方法
EP4323409A4 (en) 2021-04-14 2025-04-16 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
JP2024517642A (ja) 2021-04-20 2024-04-23 ビオンテック・ソシエタス・エウロパエア ウイルスワクチン
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
JP2024540949A (ja) 2021-10-21 2024-11-06 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
CA3234578A1 (en) 2021-10-22 2023-04-27 Advait Vijay Badkar Compositions for administration of different doses of rna
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
US20240043844A1 (en) * 2022-04-14 2024-02-08 Aro Biotherapeutics Company FN3 Domain-siRNA Conjugates with Enzyme Replacement Therapy
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
JP2025527245A (ja) 2022-08-01 2025-08-20 ビオンテック・ソシエタス・エウロパエア 両親媒性オリゴエチレングリコール（ｏｅｇ）コンジュゲート化合物を含む核酸組成物およびそのような化合物および組成物を使用する方法
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
JP2025525901A (ja) 2022-08-03 2025-08-07 バイオエヌテック エスエー 結核を予防または治療するためのｒｎａ
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024216212A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2024213776A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
CN121398842A (zh) 2023-04-14 2026-01-23 百欧恩泰欧洲股份公司 用于预防或治疗结核病的rna
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025021277A1 (en) 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
WO2025026866A1 (en) 2023-07-28 2025-02-06 BioNTech SE Rna therapeutics with reduced toxicity
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins
WO2025219859A1 (en) 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions
CN119751650B (zh) * 2025-03-07 2025-07-04 英特菲尔(成都)生物制品有限责任公司 一种长效耐热稳定重组人源化纤连蛋白及其制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524A (en) 1849-06-12 Truck eob railroad-cabs
US3455030A (en) 1966-07-11 1969-07-15 Aircraft Radio Corp Directional gyroscope
US3830721A (en) 1973-08-22 1974-08-20 Atomic Energy Commission Hollow cathode sputtering device
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5013633A (en) 1988-07-04 1991-05-07 Konica Corporation Method for developing a silver halide color photographic light-sensitive material for color proof using a specified color developing agent
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE126535T1 (de) 1990-04-05 1995-09-15 Roberto Crea ''walk-through''-mutagenese.
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JP3522923B2 (ja) 1995-10-23 2004-04-26 富士写真フイルム株式会社 ハロゲン化銀感光材料
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
DE19628705A1 (de) 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU775076B2 (en) 1998-12-10 2004-07-15 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
IL147037A0 (en) 1999-07-27 2002-08-14 Phylos Inc Peptide acceptor ligation methods
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
AU2001232267A1 (en) * 2000-02-14 2001-08-20 Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases Remedies for hepatitis c
JP2004501642A (ja) 2000-06-28 2004-01-22 グライコフィ，　インコーポレイテッド 改変された糖タンパク質を生成するための方法
EP1301538B1 (en) * 2000-07-11 2015-12-09 Research Corporation Technologies, Inc Artificial antibody polypeptides
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
MXPA03009566A (es) 2001-04-19 2004-12-06 Scripps Research Inst Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales.
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE10129369C1 (de) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
WO2003000856A2 (en) 2001-06-21 2003-01-03 Phylos, Inc. In vitro protein interaction detection systems
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
DE60329700D1 (en) 2002-10-16 2009-11-26 Scripps Research Inst Glycoproteinsynthese
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
DE10256558A1 (de) 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10302520A1 (de) 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
JP4315888B2 (ja) 2003-11-11 2009-08-19 株式会社小松製作所 車両制御装置
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
EA010501B1 (ru) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
JP2008500830A (ja) * 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
ES2372503T3 (es) 2004-07-06 2012-01-20 Bioren, Inc. Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP1934259A2 (en) 2005-10-11 2008-06-25 Ablynx N.V. Nanobodies and polypeptides against egfr and igf-ir
ATE516814T1 (de) * 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
AU2008254704A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease
EP2222846B1 (en) 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
PT2274331E (pt) 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
AR071874A1 (es) * 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
SG187225A1 (en) 2010-07-30 2013-02-28 Novartis Ag Fibronectin cradle molecules and libraries thereof

Also Published As

Publication number Publication date
ES2445695T3 (es) 2014-03-04
AU2009242038A1 (en) 2009-11-05
EP2274331A1 (en) 2011-01-19
KR20110021832A (ko) 2011-03-04
PL2439212T3 (pl) 2017-06-30
US20180127485A1 (en) 2018-05-10
AU2009242038B2 (en) 2013-05-30
JP2011522517A (ja) 2011-08-04
PT2439212T (pt) 2017-03-29
EP3173424A1 (en) 2017-05-31
CN102076713B (zh) 2015-03-25
JP2017060481A (ja) 2017-03-30
CA2723277A1 (en) 2009-11-05
US20110038866A1 (en) 2011-02-17
CN102076713A (zh) 2011-05-25
EP2274331B1 (en) 2013-11-06
US20160376345A1 (en) 2016-12-29
EP2439212B1 (en) 2016-12-21
JP6192891B2 (ja) 2017-09-06
US9296810B2 (en) 2016-03-29
BRPI0913007A2 (pt) 2019-09-24
PL2274331T3 (pl) 2014-04-30
EA201001734A1 (ru) 2011-10-31
ES2620285T3 (es) 2017-06-28
MX2010011957A (es) 2011-03-04
WO2009133208A1 (en) 2009-11-05
JP2018118978A (ja) 2018-08-02
EP2439212A1 (en) 2012-04-11
EP2383292A1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
PL2274331T3 (pl) Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
IL206356A0 (en) Improved fibronectin-based binding molecules and their use
GB0621973D0 (en) Binding molecules and uses thereof
ZA200806492B (en) Binding molecules
EP2381952A4 (en) SPARC BINDING PEPTIDES AND USES THEREOF
SG10201801945TA (en) Specific binding proteins and uses thereof
GB0815109D0 (en) Polydialkylsiloxane-bridged bi-photochromic molecules
PT2175884T (pt) Terapias de combinação empregando moléculas de ligação a gitr
IL207548A0 (en) Modified rnai polynucleotides and uses thereof
IL210804A (en) Benzylidenehydrazides and their uses
ZA200901815B (en) Binding molecules
ZA200900494B (en) DNA Molecules and methods
GB2462374B (en) Phosphate binding materials and their uses
IL200046A0 (en) Binding members for ige molecules
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
IL205357A0 (en) Improved nogo - a binding molecules and pharmceutical use thereof
GB0804459D0 (en) Immunotherapeutic methods and molecules
ZA201103981B (en) Calendar binding apparatus and related methods
GB0705795D0 (en) Cellulose binding domains and uses thereof
GB0718073D0 (en) Analysing the binding of cell membrane bound molecules
GB0711244D0 (en) Binding molecules
AU2008901357A0 (en) Novel Immunogenis Molecules and Uses Thereof - II
GB0819666D0 (en) Microarray and use thereof